Who can use Nemolizumab(Nemluvio)?

Nemolizumab (trade name Nemluvio) is a prescription medication indicated for adults with prurigo nodularis, a chronic skin condition characterized by itchy, inflamed nodules. Approved in 2024, it works by blocking the interleukin-31 receptor, reducing pruritus and skin inflammation.

Eligible users must meet specific criteria:

Age and Diagnosis: Only adults (18+ years) diagnosed with prurigo nodularis. Safety and efficacy in pediatric patients are unestablished.

Weight-Based Dosage:

Patients weighing less than 90 kg receive an initial 60 mg dose (two 30 mg injections), followed by 30 mg every 4 weeks.

Those weighing 90 kg or more require 60 mg maintenance doses every 4 weeks.

Medical Eligibility:

Prior to treatment, complete all age-appropriate vaccinations as recommended by guidelines.

Avoid live vaccines during therapy due to potential immune interference.

Contraindications: 

Contraindicated in individuals with known hypersensitivity to nemolizumab-ilto or any excipients (e.g., arginine hydrochloride, poloxamer 188).